All posts by Clay Wilemon
On June 6, 2017, DevicePharm was honored to make the opening presentation at the 2017 Spring BioBash in Austin, Texas. The presentation was titled, “So You’re Going To Launch”. It was presented to provide a guide for med-tech executives, marketers, and entrepreneurs who are launching new products, companies, and markets.
On May 18, 2017, DevicePharm and Medical Alley Association co-sponsored an event titled “Communicating Value – Marketing Success In A Value-Driven Environment”. The event, held in the iconic Guthrie Theater in downtown Minneapolis, was attended by 200 members of the Minnesota medical device, biotech, diagnostics, and pharmaceutical community.
On May 1, 2017, DevicePharm announced the opening of our new office in Austin, Texas. This office was developed to serve the growing medical technology industry in Austin, Houston, Dallas, and San Antonio.
Clay Wilemon, DevicePharm CEO and Chief Strategy Officer described the motivation for opening the Austin office, “Texas has over 700 medical device, biotech, diagnostics, and pharmaceutical companies.
On February 22, 2017, Sonex Health announced the successful completion of the first ultrasound-guided carpal tunnel release procedure in the United States using the SX-One MicroKnife™. The SX-One MicroKnife™ is an ultra-low profile surgical device that allows physicians to perform Micro-invasive carpal tunnel release (CTR) surgery through a single micro-incision (4-5 mm) using ultrasound guidance.
7D Surgical announced today that it has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada enabling the North American commercial launch of its innovative Machine-vision Image Guided Surgery (MIGS™) system for spine surgery, the 7D Surgical System. This breakthrough system is designed to simplify and speed up surgical workflow, increase surgeon control, eliminate intraoperative radiation, and deliver exceptional value.
Big Data. The term is ubiquitous in our culture and its importance was validated by the attendance of over 500 people at the leadoff panel during the OCTANe 2016 Medical Device and Investor Forum. The panel, titled “Using Big Data To Improve Patient Outcomes and Reimbursement” was hosted by DevicePharm CEO, Clay Wilemon.
Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.